Capmatinib acquisition methods and market dynamics

Capmatinib (Capmatinib), as an inhibitor of MET kinase, has been established as an advanced drug for the treatment of advanced non-small cell lung cancer (NSCLC). It is particularly suitable for adult patients with skipping mutations in MET exon 14 (METex14) who are in urgent need of systemic treatment before receiving immunotherapy or platinum-based chemotherapy.

Capmatinib is unique in that it can inhibit the phosphorylation process of c-Met wild-type and mutant variants triggered by the endogenous ligand hepatocyte growth factor thereby blocking c-Met-mediated phosphorylation of downstream signaling proteins and further inhibiting c-Met-dependent tumor cell proliferation and survival.

Although capmatinib has not yet been officially launched in the domestic market and is not covered by medical insurance, the drug is already available in Hong Kong. In Hong Kong, a box of 60 tablets of 200mg each is priced at more than 30,000 yuan, and the price may be adjusted due to exchange rate changes. If you consult a medical institution or pharmacy in Hong Kong, you are likely to find this drug.

At the same time, overseas markets also provide channels for purchasing capmatinib. For example, in the European market, the price of a box of 200mg*120 original medicines even exceeds RMB 50,000. This price will also be affected by exchange rate changes. However, it is worth noting that there are also more affordable generic capmatinib drugs in overseas markets. The ingredients of these generic drugs are highly similar to the original drugs. For example, a drug produced in Laos with 56 tablets per box and 200mg per tablet may cost only more than 3,000 yuan. Although this price may also be affected by exchange rates.